AbbVie

New deal staves off Humira biosimilar competitionA new deal between pharma giants AbbVie and Samsung Bioepis is designed to postpone competition against a biosimilar to Humira until 2023.
HIV Pipeline Prospects Getting HealthierThere is no cure for HIV, but with proper medical treatment, the disease can be controlled.
Pharma makers pull MS drug from worldwide marketIn a rare move, pharmaceutical manufacturers voluntarily recalled their drug to treat multiple sclerosis after reports of serious brain inflammation in patients.
New warning on antibiotic for heart disease patients
New warning on antibiotic for heart disease patientsFDA is advising caution before healthcare professionals prescribe a certain antibiotic to patients with heart disease due to a potential increased risk of heart problems or death that can occur years later.
How one project will change the way value is measured in healthcareThe Innovation and Value Initiative's Mark Linthicum talks to Managed Healthcare Executive (MHE) a new tool to better measure value in healthcare treatments.
European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
Will new biosimilars hurt blockbuster autoimmune drug?
Will new biosimilars hurt blockbuster autoimmune drug?New biosimilars may harm the sales of this autoimmune blockbuster.
Is a $150 Million Fine Just the Start of Trouble for AbbVie?The maker of Androgel will face a series of trials after its most recent court loss.
Evolving hepatitis C pipeline offers hope to patients
Evolving hepatitis C pipeline offers hope to patientsCost burden prompts payers to consider appropriate utilization
10 highlights from AAO 2016